Company
Our Mission: Solving the R&D crisis
It takes over a decade and more than $2 billion to bring a new drug to market.
We founded Alchemi to change this.
We're creating a future where AI will work in tandem with scientists, accelerating drug development.
In doing so we can reduce timelines, lower drug costs, and increase access to life saving medicines.
We founded Alchemi to change this.
We're creating a future where AI will work in tandem with scientists, accelerating drug development.
In doing so we can reduce timelines, lower drug costs, and increase access to life saving medicines.
Leadership
Tom Mulvey
Co-founder
Former life science investor at Vitruvian Partners, focused on partnering with CROs and CDMOs. Operating experience at CAR-T manufacturing pioneer Ori Biotech and gene therapy developer Lexeo Therapeutics. MBA from Harvard Business School.
Anuj Chadha
Co-founder
Former senior software engineer at Vecna Robotics, researcher at NASA's Jet Propulsion Lab. Focused on Robotics + Al at Caltech. Experience at Blueyard Capital. MBA from Harvard Business School.
Advisory Board
Ben Cons, PhD
Former EVP at IQVIA, Former Chair of Castor (ML platform for Clinical Trials), Special Partner at Vitruvian Partners. PhD in Pharmacology.
Mark E. Arnold, PhD
Former Director of Science at Labcorp, Former Executive Director at Bristol Myers Squibb, Former Chair of AAPS Scientific Advisory Committee. PhD in Pharmacology.
Supported by World-Class Investors
.png){kind=logo}
Join us
